Orion aktie (ORNBV) | Pressmeddelande

Orion Group Financial Statement documents 2024 and Remuneration Report published

GlobeNewswire • Igår 10:15

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.

GlobeNewswire • I förrgår 16:00

Orion to open new Biologics R&D Centre in Cambridge, UK in 2025 to support global growth strategy, considers reorganizing some work in Turku

GlobeNewswire • I förrgår 10:45

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.

GlobeNewswire • 05 Mar 16:00

Orion and Aiforia extend collaboration to preclinical study evaluations

GlobeNewswire • 05 Mar 08:00

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.

GlobeNewswire • 05 Mar 07:30

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.

GlobeNewswire • 03 Mar 15:30

Orion Corporation: Managers’ transactions – Outi Vaarala

GlobeNewswire • 28 Feb 16:45

Orion Corporation: Managers’ transactions – Niclas Lindstedt

GlobeNewswire • 28 Feb 16:00

Orion Corporation: Managers’ transactions – Hao Pan

GlobeNewswire • 27 Feb 10:00

Orion Corporation: Managers’ transactions – Satu Ahomäki

GlobeNewswire • 27 Feb 10:00

Orion Corporation: The Board of Directors of Orion Corporation decided on incentive programs for the company’s key persons

GlobeNewswire • 25 Feb 11:35

Notice to the Annual General Meeting of Orion Corporation

GlobeNewswire • 25 Feb 11:15

Orion Group Financial Statement Release January–December 2024

GlobeNewswire • 25 Feb 11:00

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.

GlobeNewswire • 19 Feb 15:00

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.

GlobeNewswire • 18 Feb 15:00

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.

GlobeNewswire • 17 Feb 14:15

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.

GlobeNewswire • 14 Feb 15:15

EU’s Urban Wastewater Treatment Directive could lead to additional costs of nearly EUR 1 billion in Finland alone, posing a serious threat to medicine availability

EU’s Urban Wastewater Treatment Directive could lead to additional costs of nearly EUR 1 billion in Finland alone, posing a serious threat t...

GlobeNewswire • 13 Feb 07:00

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.

GlobeNewswire • 12 Feb 20:00

Save the Date: Orion’s Capital Markets Day on 22 May 2025

GlobeNewswire • 10 Feb 13:00

Orion and Invenra announce discovery service and commercial license agreement to develop innovative bispecific antibody cancer therapeutics

GlobeNewswire • 30 Jan 15:00

Orion publishes Financial Statement Release for 2024 and holds a webcast on 25 February 2025

GlobeNewswire • 28 Jan 08:00

Inside information: Orion upgrades full-year outlook for 2024 and provides preliminary information on financial performance for 2024

GlobeNewswire • 15 Jan 17:25

Recommendation by the Orion Nomination Committee on the proposals to be submitted to the 2025 Annual General Meeting

GlobeNewswire • 15 Jan 09:45

79,345 Orion Corporation A shares converted into B shares

GlobeNewswire • 13 Jan 08:50

Orion’s collaboration partner Bayer submits application in China for third indication of darolutamide

GlobeNewswire • 07 Jan 08:00

Orion and Marinus terminate agreement for ganaxolone in Europe

GlobeNewswire • 30 Dec 2024 13:00

CORRECTION: Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel

GlobeNewswire • 19 Dec 2024 21:45

Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel

GlobeNewswire • 19 Dec 2024 18:00

Orion and Abilita Therapeutics announce research collaboration and option to license agreement to develop innovative antibody therapeutics

GlobeNewswire • 18 Dec 2024 16:00

Penalty payment to a member of Orion’s Board of Directors for delay in notifying managers’ transaction

GlobeNewswire • 12 Dec 2024 19:30

142,701 Orion Corporation A shares converted into B shares

GlobeNewswire • 27 Nov 2024 08:00

Orion Research Foundation grants EUR 1,109,000 for research in 2025

GlobeNewswire • 22 Nov 2024 08:00

Orion and Alligator Bioscience amend their agreement concerning two bispecific antibodies

GlobeNewswire • 19 Nov 2024 17:30

Orion Corporation: Managers’ transactions – Henrik Stenqvist

GlobeNewswire • 01 Nov 2024 08:45

Orion Group Interim Report January–September 2024

GlobeNewswire • 29 Oct 2024 11:00

Inside information: Orion terminates ODM-111 development program due to narrow therapeutic window of the molecule

GlobeNewswire • 24 Oct 2024 18:50

Orion’s collaboration partner Bayer submits application for third indication of darolutamide in the EU

GlobeNewswire • 14 Oct 2024 10:00

Orion’s near-term climate targets approved by the Science Based Targets initiative

GlobeNewswire • 30 Sep 2024 09:00

Orion’s collaboration partner Bayer submits application to U.S. FDA for third indication of darolutamide which has become the first ever Orion-originated blockbuster

Orion’s collaboration partner Bayer submits application to U.

GlobeNewswire • 26 Sep 2024 10:00

Orion and Aitia enter AI-Driven Drug Discovery and Drug Simulation Collaboration in Oncology

GlobeNewswire • 25 Sep 2024 14:00

213,285 Orion Corporation A shares converted into B shares

GlobeNewswire • 20 Sep 2024 08:30

Darolutamide plus androgen deprivation therapy significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer

Darolutamide plus androgen deprivation therapy significantly reduced the risk of radiological progression or death by 46% compared to placeb...

GlobeNewswire • 16 Sep 2024 10:30

Inside information: Orion upgrades full-year outlook for 2024

GlobeNewswire • 11 Sep 2024 08:30

Orion Corporation: Managers’ transactions – Satu Ahomäki

GlobeNewswire • 22 Aug 2024 09:30

Orion Corporation: Managers’ transactions – Niclas Lindstedt

GlobeNewswire • 21 Aug 2024 17:45

Orion Corporation: Managers’ transactions – Liisa Hurme

GlobeNewswire • 20 Aug 2024 15:15

Orion Corporation: Managers’ transactions – Hao Pan

GlobeNewswire • 15 Aug 2024 14:30

44,767 Orion Corporation A shares converted into B shares

GlobeNewswire • 14 Aug 2024 08:30

Orion Corporation: Managers’ transactions – Satu Ahomäki

GlobeNewswire • 12 Aug 2024 14:30

Orion Group Half-Year Financial Report January–June 2024

GlobeNewswire • 08 Aug 2024 11:00

Orion Corporation’s financial reporting and Annual General Meeting in 2025

GlobeNewswire • 08 Aug 2024 08:45

Orion publishes Half-Year Financial Report for January–June 2024 and holds a webcast on 8 August 2024

GlobeNewswire • 25 Jul 2024 10:00

Inside information: Phase III ARANOTE trial of darolutamide in combination with androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer meets primary endpoint

Inside information: Phase III ARANOTE trial of darolutamide in combination with androgen deprivation therapy in men with metastatic hormone-...

GlobeNewswire • 17 Jul 2024 07:30

Inside information: Orion and MSD Announce Mutual Exercise of Option Providing MSD Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Inside information: Orion and MSD Announce Mutual Exercise of Option Providing MSD Global Exclusive Rights to Opevesostat, an Investigationa...

GlobeNewswire • 01 Jul 2024 14:15

Inside information: Orion upgrades full-year outlook for 2024

GlobeNewswire • 01 Jul 2024 14:15

Orion is developing the Finnish life science industry in a unique collaboration project

GlobeNewswire • 03 Jun 2024 08:30

Orion Corporation: Change in Orion Group Executive Management Board as of 31 May 2025

GlobeNewswire • 07 May 2024 07:30

Orion Corporation: Managers’ transactions – Ari Lehtoranta

GlobeNewswire • 06 May 2024 11:00

Orion Corporation: Managers’ transactions – Kari Jussi Aho

GlobeNewswire • 06 May 2024 11:00

Orion Corporation: Managers’ transactions – Veli-Matti Mattila

GlobeNewswire • 06 May 2024 11:00

Orion Corporation: Managers’ transactions – Henrik Stenqvist

GlobeNewswire • 06 May 2024 11:00

Orion Corporation: Managers’ transactions – Maziar Mike Doustdar

GlobeNewswire • 06 May 2024 11:00

Orion Corporation: Managers’ transactions – Karen Lykke Sørensen

GlobeNewswire • 06 May 2024 11:00

Orion Corporation: Managers’ transactions – Eija Ronkainen

GlobeNewswire • 06 May 2024 11:00

Orion Corporation: Managers’ transactions – Hilpi Rautelin

GlobeNewswire • 06 May 2024 11:00

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.

GlobeNewswire • 26 Apr 2024 15:00

Composition of the Nomination Committee of Orion Corporation

GlobeNewswire • 26 Apr 2024 10:15

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.

GlobeNewswire • 25 Apr 2024 15:30

Orion Group Interim Report January–March 2024

GlobeNewswire • 25 Apr 2024 11:00

Orion Corporation: Managers’ transactions – Veli-Matti Mattila

GlobeNewswire • 22 Apr 2024 08:45

Orion publishes Interim Report for January–March 2024 and holds a webcast on 25 April 2024

GlobeNewswire • 11 Apr 2024 08:30

Change in Orion Group Executive Management Board: change in Orion's group-level functions

GlobeNewswire • 22 Mar 2024 11:30

The change negotiations concerning Orion’s Kuopio plant have been concluded – the company has decided to continue to explore the outsourcing of production at the plant

The change negotiations concerning Orion’s Kuopio plant have been concluded – the company has decided to continue to explore the outsourcing...

GlobeNewswire • 22 Mar 2024 11:00

Orion Corporation: Organising meeting of the Board of Directors

GlobeNewswire • 20 Mar 2024 16:00

Decisions taken by Orion Corporation’s Annual General Meeting on 20 March 2024

GlobeNewswire • 20 Mar 2024 15:50

Orion Corporation: Managers’ transactions – Satu Ahomäki

GlobeNewswire • 04 Mar 2024 12:00

Orion Corporation: Managers’ transactions – Olli Huotari

GlobeNewswire • 04 Mar 2024 12:00

Orion Corporation: Managers’ transactions – Jari Karlson

GlobeNewswire • 04 Mar 2024 12:00

Orion Corporation: Managers’ transactions – Liisa Hurme

GlobeNewswire • 04 Mar 2024 12:00

Orion Corporation: Managers’ transactions – Juhani Kankaanpää

GlobeNewswire • 04 Mar 2024 12:00

Orion Corporation: Managers’ transactions – Virve Laitinen

GlobeNewswire • 04 Mar 2024 12:00

Orion Corporation: Managers’ transactions – Niclas Lindstedt

GlobeNewswire • 04 Mar 2024 12:00

Orion Corporation: Managers’ transactions – Hao Pan

GlobeNewswire • 04 Mar 2024 12:00

Orion Corporation: Managers’ transactions – Outi Vaarala

GlobeNewswire • 04 Mar 2024 12:00

Orion Corporation: Transfer of 150,118 own B shares on 1 March 2024

GlobeNewswire • 01 Mar 2024 17:50

Orion Group Financial Statement documents 2023, Corporate Governance Statement and Remuneration Report published

GlobeNewswire • 26 Feb 2024 13:30

Orion and Save the Children Finland announce cooperation to promote well-being of children in Finland and globally

GlobeNewswire • 22 Feb 2024 10:00

Orion to investigate the possible outsourcing of its pharmaceutical production in Kuopio, Finland

GlobeNewswire • 19 Feb 2024 12:15

Börskollen

För dig med koll på börsen

Pressmeddelanden från Orion

Orion Group Financial Statement documents 2024 and Remuneration Report published

Orion Corporation: Managers’ transactions – Juhani Kankaanpää

Orion Corporation: Managers’ transactions – Liisa Hurme

Orion Corporation: Managers’ transactions – Niclas Lindstedt

Orion Corporation: Managers’ transactions – Julia Macharey

Orion Corporation: Managers’ transactions – René Lindell

Orion Corporation: Managers’ transactions – Olli Huotari

Orion Corporation: Managers’ transactions – Outi Vaarala

Orion Corporation: Managers’ transactions – Hao Pan

Orion Corporation: Managers’ transactions – Satu Ahomäki

Orion Corporation: Transfer of 191,911 own B shares on 10 March 2025

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion to open new Biologics R&D Centre in Cambridge, UK in 2025 to support global growth strategy, considers reorganizing some work in Turku

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion and Aiforia extend collaboration to preclinical study evaluations

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion Corporation: Managers’ transactions – Outi Vaarala

Orion Corporation: Managers’ transactions – Niclas Lindstedt

Orion Corporation: Managers’ transactions – Hao Pan

Orion Corporation: Managers’ transactions – Satu Ahomäki

Orion Corporation: The Board of Directors of Orion Corporation decided on incentive programs for the company’s key persons

Notice to the Annual General Meeting of Orion Corporation

Orion Group Financial Statement Release January–December 2024

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

EU’s Urban Wastewater Treatment Directive could lead to additional costs of nearly EUR 1 billion in Finland alone, posing a serious threat to medicine availability

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Save the Date: Orion’s Capital Markets Day on 22 May 2025

Orion and Invenra announce discovery service and commercial license agreement to develop innovative bispecific antibody cancer therapeutics

Orion publishes Financial Statement Release for 2024 and holds a webcast on 25 February 2025

Inside information: Orion upgrades full-year outlook for 2024 and provides preliminary information on financial performance for 2024

Recommendation by the Orion Nomination Committee on the proposals to be submitted to the 2025 Annual General Meeting

79,345 Orion Corporation A shares converted into B shares

Orion’s collaboration partner Bayer submits application in China for third indication of darolutamide

Orion and Marinus terminate agreement for ganaxolone in Europe

CORRECTION: Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel

Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel

Orion and Abilita Therapeutics announce research collaboration and option to license agreement to develop innovative antibody therapeutics

Penalty payment to a member of Orion’s Board of Directors for delay in notifying managers’ transaction

142,701 Orion Corporation A shares converted into B shares

Orion Research Foundation grants EUR 1,109,000 for research in 2025

Orion and Alligator Bioscience amend their agreement concerning two bispecific antibodies

Orion Corporation: Managers’ transactions – Henrik Stenqvist

Orion Group Interim Report January–September 2024

Inside information: Orion terminates ODM-111 development program due to narrow therapeutic window of the molecule

Orion’s collaboration partner Bayer submits application for third indication of darolutamide in the EU

Orion’s near-term climate targets approved by the Science Based Targets initiative

Orion’s collaboration partner Bayer submits application to U.S. FDA for third indication of darolutamide which has become the first ever Orion-originated blockbuster

Orion and Aitia enter AI-Driven Drug Discovery and Drug Simulation Collaboration in Oncology

213,285 Orion Corporation A shares converted into B shares

Darolutamide plus androgen deprivation therapy significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer

Inside information: Orion upgrades full-year outlook for 2024

Orion Corporation: Managers’ transactions – Satu Ahomäki

Orion Corporation: Managers’ transactions – Niclas Lindstedt

Orion Corporation: Managers’ transactions – Liisa Hurme

Orion Corporation: Managers’ transactions – Hao Pan

44,767 Orion Corporation A shares converted into B shares

Orion Corporation: Managers’ transactions – Satu Ahomäki

Orion Group Half-Year Financial Report January–June 2024

Orion Corporation’s financial reporting and Annual General Meeting in 2025

Orion publishes Half-Year Financial Report for January–June 2024 and holds a webcast on 8 August 2024

Inside information: Phase III ARANOTE trial of darolutamide in combination with androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer meets primary endpoint

Inside information: Orion and MSD Announce Mutual Exercise of Option Providing MSD Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Inside information: Orion upgrades full-year outlook for 2024

Orion is developing the Finnish life science industry in a unique collaboration project

Orion Corporation: Change in Orion Group Executive Management Board as of 31 May 2025

Orion Corporation: Managers’ transactions – Ari Lehtoranta

Orion Corporation: Managers’ transactions – Kari Jussi Aho

Orion Corporation: Managers’ transactions – Veli-Matti Mattila

Orion Corporation: Managers’ transactions – Henrik Stenqvist

Orion Corporation: Managers’ transactions – Maziar Mike Doustdar

Orion Corporation: Managers’ transactions – Karen Lykke Sørensen

Orion Corporation: Managers’ transactions – Eija Ronkainen

Orion Corporation: Managers’ transactions – Hilpi Rautelin